Abstract
Schizophrenic patients taking haloperidol prophylactically were screened for a haloperidol monitoring project at four medical centers. Fifty-five patients participated. Most patients had doses and plasma levels below those found in acute treatment studies; however, a sizeable minority had doses and levels that were greater than was probably needed for prophylaxis. Six percent of patients appeared to be rapid metabolizers. A regression formula was calculated for prediction of haloperidol level from daily dose. There were no apparent differences in dosing practices between two university- affiliated medical centers and two nonaffiliated centers. More research is needed to establish optimal prophylactic haloperidol levels. However, haloperidol monitoring can provide some assistance for choice of dose.
Original language | English (US) |
---|---|
Pages (from-to) | 121-126 |
Number of pages | 6 |
Journal | Annals of Clinical Psychiatry |
Volume | 4 |
Issue number | 2 |
DOIs | |
State | Published - Jan 1 1992 |